Acute phase protein concentrations in colostrum-deprived pigs immunized with subunit and commercial vaccines against Glasser's disease

作者:Martinez Martinez Sonia; Frandoloso Rafael; Gutierrez Martin Cesar B*; Lampreave Fermin; Jose Garcia Iglesias Maria; Perez Martinez Claudia; Rodriguez Ferri Elias F
来源:Veterinary Immunology and Immunopathology, 2011, 144(1-2): 61-67.
DOI:10.1016/j.vetimm.2011.07.002

摘要

Haemophilus parasuis is the etiological agent of Glasser's disease, which is characterized by fibrinous polyserositis, polyarthritis and meningitis in pigs. This study was focused on the characterization of the acute-phase response after immunization and infection of colostrum-deprived pigs with H. parasuis serovar 5, by measuring serum concentrations of three positive acute-phase proteins (APPs) (pig major acute-phase protein pig, MAP; haptoglobin, HPG; C-reactive protein, CRP) and one negative APP (apolipoprotein A-I, ApoA-I). Six experimental groups were established: a non-immunized but infected control group (CTL); two groups immunized with either a recombinant transferrin-binding protein (Tbp) A or TbpB fragment from H. parasuis Nagasaki strain (rTbpA and rTbpB, respectively); two groups immunized with native outer membrane proteins with affinity to porcine transferrin (NPAPT), one of them inoculated intramuscularly (NPAPTim) and the other intratracheally (NPAPTit), and the last group receiving a commercially available bacterin (PG). The greatest concentrations of the three positive APPs and the lowest concentration of the negative APP were detected in CTL group, as well as in those animals belonging to rTbpA or rTbpB groups that died in response to challenge. Significant differences (P < 0.005) were found in these groups when comparing challenge with the following days after it. However, no significant differences were seen for the remaining vaccinated groups (NPAPTim, NPAPTit and PG), which were effectively protected against Glasser's disease. Therefore, APPs could be used as useful biomarkers for both evaluating disease progression and determining vaccination effectiveness.

  • 出版日期2011-11-15